2021-09-006 - PLP-3 - Novel antimicrobial peptide for the treatment of multidrug resistant bacteria

Novel antimicrobial peptide for the treatment of multidrug-resistant bacteria

2021-09-002 - EPICART - Development of a DNA methylation kit for predicting the response to chimeric antigen receptor (CAR)-T cell therapy

In vitro epigenetic-based diagnostic kit to predict clinical response in patients with B-cell malignancies, such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) undergoing CAR-T cell therapy. A methylation signature has been identified, which correlates with better patient´s clinical outcome.

2021-09-001 + 2019-05-003 - SYNUCLEINOPATHIES DIAGNOSIS2 - IN VITRO METHOD FOR THE DIAGNOSIS OF SYNUCLEINOPATHIES

Lewy-Dx is a first-in-class, blood-based, rapid and minimally invasive test for DLB diagnosis. It is based on a patented, platelet-derived miRNA signature obtained from studies with blood samples from dementia patients. Lewy-Dx requires a blood sample, platelet isolation, RNA purification and miRNA amplification, inexpensive techniques usually available in clinical laboratories. Thus, once standardized and validated, our biomarker will be affordable, scalable, sustainable and easy to implement.